MECHANISMS OF RESISTANCE ARTERY STRUCTURAL REMODELING IN HYPERTENSION

高血压中阻力动脉结构重塑的机制

基本信息

  • 批准号:
    8167897
  • 负责人:
  • 金额:
    $ 16.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-01 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Background and hypothesis: Vascular disease is the major risk factor responsible for myocardial infarction in hypertensive patients. However, the molecular mechanisms that mediate vascular disease in hypertension are poorly understood. Even with the most aggressive treatment available, there is an enormous amount of residual vascular risk responsible for a large number of deaths in the UNITED STATES. Our central hypothesis is that elevated oxidative stress activates NFKB pathway, which leads to avb3-integrin shedding responsible for the increased TGFb1 bio-activity and subsequently the induction of structural wall remodeling in Ang-II-dependent hypertensive mice. We will use mesenteric resistance arteries (MRA) because they are good model reflecting changes in vessels, representative of microvessels and responsible for more than 30% blood pressure control. We have two Specific Aims under this proposal: Overall, our Specific Aim 1 is focused on the role of oxidative stress and NFKB pathways responsible for the increased collagen type 1 content, stiffness, and eutrophic remodeling induction of MRA from Ang-II-dependent hypertensive mice. Subaim 1a: treatment of Ang-II-dependent hypertensive mice apocynin or mitoquinone (MitoQ: is a mitochondria-targeted antioxidant that selectively blocks mitochondrial oxidative stress)", and the use of mice that over-express mitochondrial MnSOD infused with Ang-II to reduce NFKB pathway activation and translocation, avb3-integrin shedding, TGFb1 bioactivity, eutrophic remodeling, collagen type 1 content, and stiffness of MRA from Ang-II-dependent hypertensive mice; Subaim 1b: local down regulation of NFKB pathway by local infection of MRA from ANG II-dependent hypertensive mice with adenovirus-mediated IKB or p50/p65 NFKB subunits-siRNA delivery potentiates or reduces, respectively, avb3-integrin shedding, TGFb1 expression, collagen type 1 content, stiffness and eutrophic remodeling induction; Overall, our Specific Aim 2 is directed to determine the role of avb3-integrin shedding and TGFb1 bio-activity on collagen type 1 content, stiffness, and eutrophic remodeling induction in MRA from Ang-II-dependent hypertensive mice. To accomplish this aim, we will ascertain if: 2a: local down regulation of avb3-integrin by local infection of MRA from ANG II-dependent hypertensive mice with adenovirus-mediated avb3-integrin-siRNA delivery and the use of pharmacological inhibition of avb3-integrin reduce the increased TGFb1 bioactivity, collagen type 1 content, stiffness, and eutrophic remodeling induction of MRA from; 2b: local down regulation of TGFb1 by local infection of MRA from ANG II-dependent hypertensive mice with adenovirus-mediated TGFb1-siRNA delivery, and the use of mice overexpressing dominant negative TGFb1 receptor infused with ANG II reverse the increased collagen type 1 content, stiffness, and eutrophic remodeling induction of MRA.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KHALID MATROUGUI其他文献

KHALID MATROUGUI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KHALID MATROUGUI', 18)}}的其他基金

Interleukin 12 disruption provides beta cell and microvessel protection in type 2diabetes
白介素 12 破坏为 2 型糖尿病提供 β 细胞和微血管保护
  • 批准号:
    10219830
  • 财政年份:
    2020
  • 资助金额:
    $ 16.39万
  • 项目类别:
Stromal interaction molecule 1, immune cells, and vascular pathology in established hypertension
既定高血压中的基质相互作用分子 1、免疫细胞和血管病理学
  • 批准号:
    10206263
  • 财政年份:
    2020
  • 资助金额:
    $ 16.39万
  • 项目类别:
Stromal interaction molecule 1, immune cells, and vascular pathology in established hypertension
既定高血压中的基质相互作用分子 1、免疫细胞和血管病理学
  • 批准号:
    10673211
  • 财政年份:
    2020
  • 资助金额:
    $ 16.39万
  • 项目类别:
Stromal interaction molecule 1, immune cells, and vascular pathology in established hypertension
既定高血压中的基质相互作用分子 1、免疫细胞和血管病理学
  • 批准号:
    10455479
  • 财政年份:
    2020
  • 资助金额:
    $ 16.39万
  • 项目类别:
Interleukin 12 disruption provides beta cell and microvessel protection in type 2diabetes
白介素 12 破坏为 2 型糖尿病提供 β 细胞和微血管保护
  • 批准号:
    10650143
  • 财政年份:
    2020
  • 资助金额:
    $ 16.39万
  • 项目类别:
Interleukin 12 disruption provides beta cell and microvessel protection in type 2diabetes
白介素 12 破坏为 2 型糖尿病提供 β 细胞和微血管保护
  • 批准号:
    10444975
  • 财政年份:
    2020
  • 资助金额:
    $ 16.39万
  • 项目类别:
Mechanisms of Coronary Arteriolar Dysfunction in Type 2 Diabetes
2 型糖尿病冠状动脉功能障碍的机制
  • 批准号:
    8383472
  • 财政年份:
    2010
  • 资助金额:
    $ 16.39万
  • 项目类别:
Mechanisms of Coronary Arteriolar Dysfunction in Type 2 Diabetes
2 型糖尿病冠状动脉功能障碍的机制
  • 批准号:
    7792312
  • 财政年份:
    2010
  • 资助金额:
    $ 16.39万
  • 项目类别:
Mechanisms of Coronary Arteriolar Dysfunction in Type 2 Diabetes
2 型糖尿病冠状动脉功能障碍的机制
  • 批准号:
    8013945
  • 财政年份:
    2010
  • 资助金额:
    $ 16.39万
  • 项目类别:
Mechanisms of Coronary Arteriolar Dysfunction in Type 2 Diabetes
2 型糖尿病冠状动脉功能障碍的机制
  • 批准号:
    8611809
  • 财政年份:
    2010
  • 资助金额:
    $ 16.39万
  • 项目类别:

相似海外基金

Enhancing gamete cryoprotective properties of graphene oxide by dual functionalization with antioxidants and non-penetrating cryoprotectant molecules
通过抗氧化剂和非渗透性冷冻保护剂分子的双重功能化增强氧化石墨烯的配子冷冻保护特性
  • 批准号:
    24K18002
  • 财政年份:
    2024
  • 资助金额:
    $ 16.39万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
SBIR Phase I: Sustainable antioxidants for industrial process fluids
SBIR 第一阶段:工业过程流体的可持续抗氧化剂
  • 批准号:
    2222215
  • 财政年份:
    2023
  • 资助金额:
    $ 16.39万
  • 项目类别:
    Standard Grant
Development of a new bone augmentation method that enables long-term survival and long-term functional expression of transplanted cells by antioxidants
开发一种新的骨增强方法,通过抗氧化剂使移植细胞能够长期存活和长期功能表达
  • 批准号:
    23K09272
  • 财政年份:
    2023
  • 资助金额:
    $ 16.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Non-Invasive Probing Cellular Oxidative Stress and Antioxidants Therapeutic Effectiveness
非侵入性探测细胞氧化应激和抗氧化剂的治疗效果
  • 批准号:
    10652764
  • 财政年份:
    2023
  • 资助金额:
    $ 16.39万
  • 项目类别:
Mitochondria-targeting Novel Cationic Hydrazone Antioxidants for the Treatment of Preeclampsia
线粒体靶向新型阳离子腙抗氧化剂用于治疗先兆子痫
  • 批准号:
    10730652
  • 财政年份:
    2023
  • 资助金额:
    $ 16.39万
  • 项目类别:
Effects of different doses of antioxidants(Vitamin E) intake on exercise induced oxidative stress, antioxidative capacity and chronic inflammation
不同剂量抗氧化剂(维生素E)摄入对运动引起的氧化应激、抗氧化能力和慢性炎症的影响
  • 批准号:
    22K11609
  • 财政年份:
    2022
  • 资助金额:
    $ 16.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Contribution of antioxidants to regeneration of rotator cuff insertion
抗氧化剂对肩袖插入再生的贡献
  • 批准号:
    22K16720
  • 财政年份:
    2022
  • 资助金额:
    $ 16.39万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Latent Antioxidants for Environmentally Responsible Polymer Formulations
用于环保聚合物配方的潜在抗氧化剂
  • 批准号:
    RGPIN-2018-04107
  • 财政年份:
    2022
  • 资助金额:
    $ 16.39万
  • 项目类别:
    Discovery Grants Program - Individual
Polyunsaturated fatty acid (PUFA), inflammation and antioxidants
多不饱和脂肪酸 (PUFA)、炎症和抗氧化剂
  • 批准号:
    RGPIN-2019-05674
  • 财政年份:
    2022
  • 资助金额:
    $ 16.39万
  • 项目类别:
    Discovery Grants Program - Individual
Suppressed methemoglobin formation of artificial red cell by liposomal antioxidants and its mechanism.
脂质体抗氧化剂抑制人工红细胞高铁血红蛋白形成及其机制
  • 批准号:
    22K12824
  • 财政年份:
    2022
  • 资助金额:
    $ 16.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了